Literature DB >> 62582

Labetalol in long-term treatment of hypertension.

B N Prichard, A J Boakes.   

Abstract

1 Labetalol, a beta- and alpha-adrenoreceptor-blocking drug, has been used in the treatment of hypertension in a total of 32 patients for over 4.5 yr, 14 patients for 3 yr or more. 2 Labetalol seems to have a similarly potency of methyldopa and the adrenergic neurone-blocking drugs. 3 Postural hypotension was only observed at doses over 2 g/d. It was the reason for stopping treatment in two patients. 4 Dosage varied; average 889 mg/d, range 75-3,200 mg. Tolerance did not develop. 5 Side-effects led to drug withdrawal in four patients

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62582

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  29 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 3.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

4.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Labetalol in essential hypertension.

Authors:  A Breckenridge; M Orme; M J Serlin; M Maciver
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

7.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02

Review 8.  Clinical experience with dual-acting drugs in hypertension.

Authors:  K H Rahn
Journal:  Clin Investig       Date:  1992

9.  Effects of combined alpha- and beta-blockade by labetalol in patients with coronary artery disease.

Authors:  M Condorelli; G Brevetti; M Chiariello; D Miceli; G Lavecchia; G Paudice; S Verrienti
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors:  D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.